Journal: Translational Oncology
Article Title: Multimodal urinary biomarker panel achieves superior prostate cancer detection accuracy and reduces unnecessary biopsies
doi: 10.1016/j.tranon.2025.102582
Figure Lengend Snippet: Inflammatory Markers in Prostate Cancer. Inflammatory marker analyses were conducted to evaluate the systemic immune response of prostate cancer and the association between inflammation and miRNA expression and their impact on the tumor microenvironment. Box plots show the NLR and CRP levels measured with Sysmex XN-3000 and CardioPhase® respectively. Data is presented as median with IQR. Statistical significance was evaluated by Kruskal-Wallis test followed Dunn's multiple comparisons. In PCa patients, Spearman’s rank correlation was done to evaluate the relationship between NLR and miRNA expression. The progressive elevation of NLR control is first observed in (1.75) and a further increase in BPH (1.92) and PCa (2.58). The increase in NLR was further stratified based on Gleason score risk categories, which shows the highest value in aggressive disease (3.12 in high risk). The elevation of CRP in PCa compared with controls is not specific to BPH patients. There is positive correlation of NLR with oncogenic miRNAs (miR-21–5p: r = 0.32; miR-375: r = 0.29) suggesting possible mechanistic links between systemic inflammation and tumor biology. Overall, the NLR is a simple and inexpensive marker correlated with disease aggressiveness. Its potential to complement miRNA expression profile and aid in risk stratification and personalization of treatment in prostate cancer is a reassuring step forward in the field of oncology.
Article Snippet: Box plots show the NLR and CRP levels measured with Sysmex XN-3000 and CardioPhase® respectively.
Techniques: Marker, Expressing, Control
